Cargando…
Impact of Insurance and Treatment Regimens on HCV Outcome: Long-term Follow-up Study
BACKGROUND: Directly acting agents (DAA) have revolutionized the treatment of Hepatitis C infection. However the access to appropriate drugs has been a barrier to therapy. Our objective of this study was to find the impact of insurance type and treatment regimen on outcome in patients with hepatitis...
Autores principales: | Mukka, Mallikarjuna, Akram, Sami, Koirala, Janak |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5632094/ http://dx.doi.org/10.1093/ofid/ofx163.398 |
Ejemplares similares
-
Long‐term follow‐up of clinical trial patients treated for chronic HCV infection with daclatasvir‐based regimens
por: Reddy, K. Rajender, et al.
Publicado: (2017) -
1069. Loss to follow-up does not impact SVR for HCV infection
por: Kottilil, Sita K, et al.
Publicado: (2020) -
87. Heart and Lung Transplants From HCV-Viremic Donors to Uninfected Patients: Longer-Term Follow-Up
por: Woolley, Ann E, et al.
Publicado: (2019) -
Family Spillovers and Long-Term Care Insurance
por: Coe, Norma, et al.
Publicado: (2020) -
2274. Comparison of Clinical Outcomes in Patients with Extensively Drug-Resistant Pseudomonas aeruginosa Pneumonia Treated with Aminoglycosides vs. Ceftolozane/Tazobactam
por: Pervin, Najwa, et al.
Publicado: (2019)